COVID-19 and Diabetes Mellitus: May Old Anti-diabetic Agents Become the New Philosopher’s Stone?
Authors:
Open Access
- 7 May 2020
- journal article
- letter
- Published by Springer Nature in Diabetes Therapy
- Vol. 11 (6) , 1195-1197
Abstract
Corona virus infectious disease (COVID-19) is a new pandemic. In subjects with diabetes mellitus, infection may be more frequent and severe. We discuss the potential contribution of two traditional oral antidiabetic agents, metformin and pioglitazone, to the improvement of liver injury in COVID-19. Clearly, further experience is needed to shed light on these hypotheses.Keywords
This publication has 20 references indexed in Scilit:
- Pioglitazone ameliorates hepatic damage in irradiated ratsviaregulating anti-inflammatory and antifibrogenic signalling pathwaysFree Radical Research, 2019
- Hepatoprotective activity of metformin: A new mission for an old drug?European Journal of Pharmacology, 2019
- Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic SteatosisScientific Reports, 2017
- Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate-activated protein kinaseOncotarget, 2017
- Therapies in non‐alcoholic steatohepatitis (NASH)Liver International, 2017
- Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trialTrials, 2016
- Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus CoinfectionAIDS Research and Human Retroviruses, 2015
- Metformin: a cheap and well‐tolerated drug that provides benefits for viral infectionsHIV Medicine, 2012
- Pioglitazone Decreases Hepatitis C Viral Load in Overweight, Treatment Naïve, Genotype 4 Infected-Patients: A Pilot StudyPLOS ONE, 2012
- Pharmacodynamic and pharmacokinetic properties of diazepam in horsesAmerican Journal of Veterinary Research, 1982